| 新股发行及今日交易提示 | 2025/10/23 | 星期四 | | | | | | --- | --- | --- | --- | --- | --- | --- | | 2025/10/23 | 内地市场权益提示 | 类别 | 证券代码 | 证券简称 | 权益日期 | 最新公告链接 | | https://www.cninfo.com.cn/new/disclosure/detail?stockCode=688585&announcementId=122472 | 要约收购 | 688585 | 上纬新材 | 要约申报期：2025年9月29日至2025年10月28日 | 1731&orgId=9900042956&announcementTime=2025 | -10-21 | | http://www.cninfo.com.cn/new/disclosure/detail?stockCode=600629&announcementId=122472 | 600629 | 华建集团 | 4006&orgId=gssh0600629&announcementTime=2025 | -10-22 | | ...

今日涨跌幅居前的概念板块 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 688062 | 迈威生物 | -5.53 | 7.46 | -6948.29 | | 002007 | 华兰生物 | -1.41 | 1.37 | -6643.00 | | 300558 | 贝达药业 | -3.26 | 1.78 | -5441.57 | | 300122 | 智飞生物 | -0.25 | 1.08 | -3370.31 | | 300683 | 海特生物 | -7.15 | 11.21 | -3346.26 | | 688166 | 博瑞医药 | -1.31 | 1.41 | -3278.54 | | 000513 | 丽珠集团 | -0.56 | 0.84 | -2709.13 | | 300723 | 一品红 | -5.07 | 2.71 | -2659.12 | | 688266 | 泽璟制药 | -3.41 | 0.88 | -2615.23 | | 603707 | 健友股份 | -4.00 ...

在A股创新药赛道，博瑞医药上演了一场惊心动魄的资本大戏。 短短十多个交易日，公司股价几近腰斩，而此前几个月内，股价又一度暴涨近300%。如此罕见的超级"过山车"，背后究竟发生了什么？ 博瑞医药，曾站上创新药大风口。 2025年8月之前，创新药指数一路狂飙，涨超60%。板块内，多达70家公司股价实现翻倍。其中，博瑞医药为涨幅惊人的三倍股，与之相伴的还有暴涨五倍 的昂利康、六倍的广生堂，乃至十倍的舒泰神。 除起步估值偏低外，这波创新药行情的导火索是中国药企BD交易进展迅猛。这在一定程度上对冲了国内集采压力。据医药魔方，截至8月底，中国创新药 license-out交易数量为83项，总金额为845亿美元，占全球半壁江山，规模远超2024年全年的488亿美元。 中国创新药BD出海数量与金额，来源：医药魔方 减肥药又正是创新药中炙手可热的新兴赛道。巴克莱银行乐观预测，到2030年，全球减重市场规模有望膨胀至1500亿美元。海外巨头诺和诺德、礼来凭借司 美格鲁肽、替尔泊肽，销售额连创新高，进一步点燃了A股市场对减肥药概念的炒作热情。 恰逢其时，博瑞医药大力转型创新药，其核心在研产品BGM0504（包括降糖、减重适应症）在 ...

Core Insights - The attitude of foreign capital towards Chinese medical assets has dramatically reversed within a year, shifting from a neutral to a positive outlook on the biotechnology sector in China [1][3][7] Group 1: Market Sentiment Shift - Morgan Stanley's report titled "China Biotech: Innovation Dawn" indicates that China's biotechnology sector is now viewed as a critical part of the global new drug supply chain, with projected pharmaceutical revenues reaching $34 billion by 2030 and $220 billion by 2040 [1][3] - The number of foreign institutions conducting research on Chinese biotech companies has surged, with notable firms like State Street Bank and BlackRock showing increased interest [1][2] - The collective buying actions of foreign investors, such as JPMorgan and Citigroup, reflect a significant shift in sentiment towards Chinese innovative drug companies [2][5] Group 2: Investment Dynamics - The efficiency of converting research interest into actual holdings is evident, as seen in the stock price surge of WuXi AppTec, which rose by 6.52% due to increased foreign investment [2] - Major foreign investors have increased their holdings in key Chinese biotech firms, indicating a trend of strategic accumulation among top foreign capital [5][6] - The report highlights that foreign capital is now viewing specific sectors in China as essential assets in the global technology race, with over 90% of U.S. investors expressing plans to increase exposure to Chinese stocks, particularly in biotechnology [6][7] Group 3: Industry Evolution - The narrative surrounding China's pharmaceutical industry has shifted from being cost-driven to innovation-driven, acknowledging the significant advancements in the sector [3][4] - Morgan Stanley and Goldman Sachs both emphasize the growing recognition of China's innovative capabilities in biotechnology, with expectations that several leading biotech firms will reach breakeven by 2025-2026 [4][8] - The report outlines that the Chinese biotech sector is becoming a key player in filling the revenue gaps created by patent expirations in multinational corporations (MNCs), with an estimated $115 billion revenue loss due to patent cliffs by 2035 [8][10] Group 4: Future Projections - By 2040, China's share of FDA-approved drugs is expected to rise from 5% to 35%, with a projected global sales figure exceeding $1.22 trillion even in the most pessimistic scenarios [25][27] - The report anticipates that the collaboration between MNCs and Chinese biotech firms will intensify, driven by the need to address revenue shortfalls from patent expirations [10][14] - The overall improvement in clinical trial data integrity and the increasing number of new molecular entities launched in China are contributing to a more favorable investment landscape [20][22]

New Stock Offerings - The tender offer for Shangwei New Materials (688585) is open from September 29, 2025, to October 28, 2025[1] - BoRui Pharmaceutical (688166) and Nanxin Pharmaceutical (688189) announced significant abnormal fluctuations on October 10, 2025[1] - Tianpu Co., Ltd. (605255) and Pingtan Development (000592) issued announcements on October 21, 2025[1] Market Alerts - Multiple companies, including AnTong Holdings (600179) and GuoXin New Energy (600617), issued announcements on October 21, 2025, regarding their stock performance[1] - A total of 20 companies reported abnormal fluctuations in their stock prices, indicating potential volatility in the market[2] - The report highlights the importance of monitoring these fluctuations for investment strategies and risk management[2]

10月21日，博瑞医药（维权）盘中上涨2.06%，截至10:46，报52.63元/股，成交1.18亿元，换手率 0.54%，总市值222.68亿元。 资金流向方面，主力资金净流出390.74万元，特大单买入695.26万元，占比5.88%，卖出795.67万元，占 比6.73%；大单买入2763.55万元，占比23.37%，卖出3053.89万元，占比25.82%。 资料显示，博瑞生物医药(苏州)股份有限公司位于江苏省苏州工业园区星湖街218号纳米科技园C25-C28 栋，成立日期2001年10月26日，上市日期2019年11月8日，公司主营业务涉及研发和生产高端仿制药和 原创性新药。主营业务收入构成为：产品销售收入89.90%，技术权益及服务收入6.77%，其他(补 充)3.33%。 博瑞医药所属申万行业为：医药生物-化学制药-原料药。所属概念板块包括：多肽药、原料药、创新 药、生物医药、合成生物等。 截至6月30日，博瑞医药股东户数9568.00，较上期减少10.11%；人均流通股44185股，较上期增加 11.32%。2025年1月-6月，博瑞医药实现营业收入5.37亿元，同比减少18.28%；归母净利 ...

（文章来源：证券日报） 证券日报网讯 10月20日晚间，博瑞医药发布公告称，公司于2025年10月15日召开第四届董事会第十三 次会议，审议通过了《关于终止公司2024年度向特定对象发行A股股票事项并撤回申请文件的议案》， 关联董事袁建栋先生已回避表决。会议同意公司终止本次向特定对象发行A股股票并撤回申请文件事 项。2025年10月17日，公司收到上交所出具的《关于终止对博瑞生物医药（苏州）股份有限公司向特定 对象发行股票审核的决定》（上证科审（再融资）〔2025〕135号），根据有关规定，上交所决定终止 对公司向特定对象发行股票的审核。 ...

Group 1 - The core point of the article is that Borui Pharmaceutical has decided to terminate its plan for a specific issuance of A-shares for 2024 due to a comprehensive assessment of the current market environment and its own operational status [4][6] - The company had previously planned to raise 500 million yuan through this issuance, which was to be fully subscribed by its actual controller, Yuan Jiandong [4] - The initial plan was approved in May 2024, but there was no substantial progress over the year, leading to multiple revisions of the issuance plan before the company voluntarily withdrew its application [4] Group 2 - Borui Pharmaceutical is planning to issue H-shares and list on the Hong Kong Stock Exchange in 2025 to accelerate its internationalization and enhance its capital strength [6] - The company has appointed Ernst & Young as the auditing firm for this upcoming Hong Kong listing [6] - Established for over 20 years, Borui Pharmaceutical's product portfolio includes innovative drugs across various therapeutic areas, including metabolism, antiviral, antifungal, immunosuppressive, respiratory, and oncology [6] Group 3 - As of now, Borui Pharmaceutical has a market capitalization of approximately 24.5 billion yuan and has completed three rounds of financing since its IPO in November 2019 [6] - The company received a warning letter from the China Securities Regulatory Commission in June due to improper management of raised funds [6]

证券代码：688166 证券简称：博瑞医药 公告编号：2025-090 特此公告。 博瑞生物医药（苏州）股份有限公司董事会 2025 年 10 月 21 日 博瑞生物医药（苏州）股份有限公司（以下简称"公司"）于2025年10月15 日召开第四届董事会第十三次会议，审议通过了《关于终止公司2024年度向特定 对象发行A股股票事项并撤回申请文件的议案》，关联董事袁建栋先生已回避表决。 会议同意公司终止本次向特定对象发行A股股票并撤回申请文件事项。具体内容 详见于2025年10月16日公司在上海证券交易所（以下简称"上交所"）网站 （www.sse.com.cn）披露的《关于终止公司2024年度向特定对象发行A股股票事 项并撤回申请文件的公告》（公告编号：2025-088）。 2025 年 10 月 15 日，公司和保荐人国联民生证券承销保荐有限公司向上交 所提交了《博瑞生物医药（苏州）股份有限公司关于撤回向特定对象发行股票并 在科创板上市申请文件的申请》和《国联民生证券承销保荐有限公司关于撤回博 瑞生物医药（苏州）股份有限公司向特定对象发行股票并在科创板上市申请文件 的申请》，分别申请撤回向特定对象发行股票的申 ...

Core Viewpoint - The company, Borui Biopharmaceutical (Suzhou) Co., Ltd., has decided to terminate its plan for a specific issuance of A-shares for the year 2024 and has withdrawn its application documents [1] Group 1 - The fourth meeting of the fourth board of directors was held to review and approve the resolution to terminate the issuance of A-shares [1] - Related director Yuan Jiandong abstained from voting on the resolution [1] - The company and its sponsor, Guolian Minsheng Securities Co., Ltd., submitted applications to the Shanghai Stock Exchange to withdraw the application documents and revoke the sponsorship work [1] Group 2 - On October 21, the company announced that it had received a decision from the Shanghai Stock Exchange to terminate the review of its specific issuance of shares [1] - The Shanghai Stock Exchange made this decision based on relevant regulations [1]